Possible mechanisms make clinical sense The simulated mechanisms outlined in this new research are plausible: GLP-1 receptor agonism may up-regulate synaptic recovery or alter SNAP-25 phosphorylation, thereby shortening the effective blockade period of BoNT-A Lean-mass decline is common in GLP-1 induced weight loss and could alter diffusion or the volume of distribution of injected toxin, reducing dwell-time in muscle tissue Metabolic alterations, such as changes in clearance and/or muscle repair dynamics, may accelerate neuromuscular recovery
Unlike most tablets, oral semaglutide requires a very specific routine
In contrast, indirect effects might occur through changes in body weight, energy levels, mood, or other factors that can secondarily influence sexual function
It does not, however, replicate the larger average weight losses shown in human clinical trials of prescription GLP1 therapies such as semaglutide (Ozempic) (injectable)
Results should be comparable
The key is to lean into learning during your time on the medication
